Instruments for Estimation of Health-Related Quality of Life in Patients with Skull Base Neoplasms

ABSTRACT

With advances in treatment of patients with tumors of the skull base and associated improvement in length of survival, the need for assessment of quality of life (QOL) is becoming increasingly apparent. A thorough assessment of QOL, including functional, physical, social, and emotional status, as well as disease-specific symptoms, allows for comparison of treatments and informs treatment decisions. In addition, it allows for problems following intervention to be identified and addressed, thereby assisting patients in their pursuits of returning to their normal activities and level of functioning. Although health care providers and researchers are increasingly aware of the need to assess patients' QOL, few standardized measures exist with which to perform a comprehensive assessment of QOL in patients with skull base neoplasms. Further research is needed, including prospective trials using reliable and valid measures tapping various aspects of QOL and specific symptoms unique to patients with tumors of the skull base.

Skull base tumor - quality of life

REFERENCES

• 1 Gil Z, Abergel A, Spektor S, Shabtai E, Khafif A, Fliss D M. Development of a cancer-specific anterior skull base quality-of-life questionnaire.  J Neurosurg. 2004;  100 813-819
• 2 Meyers C A, Geara F, Wong P, Morrison W H. Neurocognitive effects of therapeutic irradiation for base of skull tumors.  Int J Radiat Oncol Biol Phys. 2000;  46 51-55
• 3 Cusimano M D. Quality-of-life assessment in patients with lesions of the cranial base.  Skull Base Surg. 1999;  9 259-264
• 4 Meyers C A, Hess K R. Multifaceted end points in brain tumor clinical trials: cognitive deterioration precedes MRI progression.  Neuro-oncol. 2003;  5 89-95
• 5 Murphy B A, Ridner S, Wells N, Dietrich M. Quality of life research in head and neck cancer: a review of the current state of the science.  Crit Rev Oncol Hematol. 2007;  62 251-267
• 6 Gil Z, Abergel A, Spektor S, Khafif A, Fliss D M. Patient, caregiver, and surgeon perceptions of quality of life following anterior skull base surgery.  Arch Otolaryngol Head Neck Surg. 2004;  130 1276-1281
• 7 Yugueros P, Finical S J, Johnson C H. Use of microvascular free-tissue transfer following ablative surgery of the skull base.  J Reconstr Microsurg. 2000;  16 3-6
• 8 Natarajan S K, Sekhar L N, Schessel D, Morita A. Petroclival meningiomas: multimodality treatment and outcomes at long-term follow-up.  Neurosurgery. 2007;  60 965-979 discussion 979-981
• 9 Lang D A, Honeybul S, Neil-Dwyer G, Evans B T, Weller R O, Gill J. The extended transbasal approach: clinical applications and complications.  Acta Neurochir (Wien). 1999;  141 579-585
• 10 Mathiesen T, Gerlich Å, Kihlström L, Svensson M, Bagger-Sjöbäck D. Effects of using combined transpetrosal surgical approaches to treat petroclival meningiomas.  Neurosurgery. 2007;  60 982-991 discussion 991-992
• 11 Raso J L, Gusmão S. Transbasal approach to skull base tumors: evaluation and proposal of classification.  Surg Neurol. 2006;  65(Suppl 1) S1:33-S1:37 discussion 1:37-1:38
• 12 Roser F, Ebner F H, Ritz R, Samii M, Tatagiba M S, Nakamura M. Management of skull based meningiomas in the elderly patient.  J Clin Neurosci. 2007;  14 224-228
• 13 Ware Jr J E, Sherbourne C D. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection.  Med Care. 1992;  30 473-483
• 14 Neil-Dwyer G, Lang D A, Davis A. Outcome from complex neurosurgery: an evidence based approach.  Acta Neurochir (Wien). 2000;  142 367-371
• 15 Baumann I, Polligkeit J, Blumenstock G, Mauz P S, Zalaman I M, Maassen M M. Quality of life after unilateral acoustic neuroma surgery via middle cranial fossa approach.  Acta Otolaryngol. 2005;  125 585-591
• 16 da Cruz M J, Moffat D A, Hardy D G. Postoperative quality of life in vestibular schwannoma patients measured by the SF36 Health Questionnaire.  Laryngoscope. 2000;  110 151-155
• 17 Kelleher M O, Fernandes M F, Sim D W, O'Sullivan M G. Health-related quality of life in patients with skull base tumours.  Br J Neurosurg. 2002;  16 16-20
• 18 Aaronson N K, Ahmedzai S, Bergman B et al.. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology.  J Natl Cancer Inst. 1993;  85 365-376
• 19 Irving R M, Beynon G J, Viani L, Hardy D G, Baguley D M, Moffat D A. The patient's perspective after vestibular schwannoma removal: quality of life and implications for management.  Am J Otol. 1995;  16 331-337
• 20 Cella D F, Tulsky D S, Gray G et al.. The Functional Assessment of Cancer Therapy scale: development and validation of the general measure.  J Clin Oncol. 1993;  11 570-579
• 21 DeMonte F. Functional outcomes in skull base surgery. What is acceptable?.  Clin Neurosurg. 2001;  48 340-350
• 22 DeMonte F. Evolving role of skullbase surgery for patients with low and high grade malignancies.  J Neurooncol. 2004;  69 191-198
• 23 Hassan S J, Weymuller Jr E A. Assessment of quality of life in head and neck cancer patients.  Head Neck. 1993;  15 485-496
• 24 Rogers S N, Gwanne S, Lowe D, Humphris G, Yueh B, Weymuller Jr E A. The addition of mood and anxiety domains to the University of Washington quality of life scale.  Head Neck. 2002;  24 521-529
• 25 Martinez-Devesa P, Barnes M L, Alcock C J, Kerr R S, Milford C A. Evaluation of quality of life and psychiatric morbidity in patients with malignant tumours of the skull base.  J Laryngol Otol. 2006;  120 1049-1054
• 26 Rigby P L, Shah S B, Jackler R K, Chung J H, Cooke D D. Acoustic neuroma surgery: outcome analysis of patient-perceived disability.  Am J Otol. 1997;  18 427-435
• 27 Gil Z, Abergel A, Spektor S et al.. Quality of life following surgery for anterior skull base tumors.  Arch Otolaryngol Head Neck Surg. 2003;  129 1303-1309
• 28 Fliss D M, Abergel A, Cavel O, Margalit N, Gil Z. Combined subcranial approaches for excision of complex anterior skull base tumors.  Arch Otolaryngol Head Neck Surg. 2007;  133 888-896
• 29 Weitzner M A, Meyers C A, Gelke C K, Byrne K S, Cella D F, Levin V A. The Functional Assessment of Cancer Therapy (FACT) scale. Development of a brain subscale and revalidation of the general version (FACT-G) in patients with primary brain tumors.  Cancer. 1995;  75 1151-1161
• 30 Castellon S A, Ganz P A, Bower J E, Petersen L, Abraham L, Greendale G A. Neurocognitive performance in breast cancer survivors exposed to adjuvant chemotherapy and tamoxifen.  J Clin Exp Neuropsychol. 2004;  26 955-969
• 31 Jenkins V, Shilling V, Deutsch G et al.. A 3-year prospective study of the effects of adjuvant treatments on cognition in women with early stage breast cancer.  Br J Cancer. 2006;  94 828-834
• 32 Schagen S B, Muller M J, Boogerd W, Van Dam F S. Cognitive dysfunction and chemotherapy: neuropsychological findings in perspective.  Clin Breast Cancer. 2002;  3(Suppl 3) S100-S108
• 33 Houston W S, Bondi M W. Potentially reversible cognitive symptoms in older adults. In: Attix KD, Welsh-Bomer K Geriatric Neuropsychology Assessment and Intervention. New York; Guilford Press 2006: 103-131
• 34 Deschler D G, Walsh K A, Friedman S, Hayden R E. Quality of life assessment in patients undergoing head and neck surgery as evaluated by lay caregivers.  Laryngoscope. 1999;  109 42-46
• 35 Sneeuw KCA, Aaronson N K, Osoba D et al.. The use of significant others as proxy raters of the quality of life of patients with brain cancer.  Med Care. 1997;  35 490-506